LG121071

Last updated
LG121071
LG-121071.svg
Clinical data
Other namesLG-121071; LGD-121071
Identifiers
  • 6-Ethyl-4-(trifluoromethyl)-1H,2H,6H,7H,8H,9H-pyrido[3,2-g]quinolin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H15F3N2O
Molar mass 296.293 g·mol−1
3D model (JSmol)
  • CCC1CCNC2=C1C=C3C(=CC(=O)NC3=C2)C(F)(F)F
  • InChI=1S/C15H15F3N2O/c1-2-8-3-4-19-12-7-13-10(5-9(8)12)11(15(16,17)18)6-14(21)20-13/h5-8,19H,2-4H2,1H3,(H,20,21)
  • Key:SZPPQFARTYXRKU-UHFFFAOYSA-N

LG121071 (or LGD-121071) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals that was first described in 1999 and was the first orally active nonsteroidal androgen to be discovered. [1] [2] It is a tricyclic quinolone derivative, structurally distinct from other nonsteroidal AR agonists like andarine and enobosarm (ostarine). [2] The drug acts as a high-affinity full agonist of the androgen receptor (AR) (Ki = 17 nM), [2] with a potency and efficacy that is said to be equivalent to that of dihydrotestosterone (DHT). [3] Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by 5α-reductase in androgenic tissues (nor aromatized into estrogenic metabolites), and for this reason, show tissue-selective androgenic effects. [4] In accordance, they are said to possess full anabolic activity with reduced androgenic activity, similarly to anabolic-androgenic steroids. [5]

The in vitro metabolism of LG121071 has been characterized in anticipation of its possible use as a doping agent. [5] [6]

See also

References

  1. ↑ Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, Jones TK (January 1999). "Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)". Journal of Medicinal Chemistry. 42 (2): 210–212. doi:10.1021/jm9806648. PMID   9925725.
  2. 1 2 3 Gao W, Kim J, Dalton JT (August 2006). "Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands". Pharmaceutical Research. 23 (8): 1641–1658. doi:10.1007/s11095-006-9024-3. PMC   2072875 . PMID   16841196.
  3. ↑ Chengalvala M, Oh T, Roy AK (2005). "Selective androgen receptor modulators". Expert Opinion on Therapeutic Patents. 13 (1): 59–66. doi:10.1517/13543776.13.1.59. ISSN   1354-3776. S2CID   219188263.
  4. ↑ Elbers JM, Grootenhuis AJ (April 2003). "New tissue-selective androgens: perspectives in the treatment of androgen deficits". Annales d'Endocrinologie. 64 (2): 183–188. PMID   12773961.
  5. 1 2 Knoop A, Krug O, Vincenti M, Schänzer W, Thevis M (2015). "In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry". European Journal of Mass Spectrometry. 21 (1): 27–36. doi:10.1255/ejms.1328. PMID   25906032. S2CID   29918434.
  6. ↑ Gerace E, Salomone A, Fasano F, Costa R, Boschi D, Di Stilo A, Vincenti M (April 2011). "Validation of a GC/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis". Analytical and Bioanalytical Chemistry. 400 (1): 137–144. doi:10.1007/s00216-010-4569-8. hdl: 2318/86557 . PMID   21165606. S2CID   43268790.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.